Skip to main content

Absci Corporation (ABSI)

NASDAQ: ABSI · IEX Real-Time Price · USD
11.65 -0.21 (-1.77%)
Oct 22, 2021 4:00 PM EDT - Market closed
Market Cap1.05B
Revenue (ttm)5.27M
Net Income (ttm)-22.66M
Shares Out90.38M
EPS (ttm)-0.25
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume124,540
Open11.78
Previous Close11.86
Day's Range11.41 - 12.43
52-Week Range9.62 - 31.53
Betan/a
Analystsn/a
Price Targetn/a
Est. Earnings DateNov 9, 2021

About ABSI

Absci was founded with the goal of creating better medicines and helping them reach patients sooner. With our AI-powered Integrated Drug Creation Platform we enable the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. We leverage proprietary synthetic biology technologies and deep learning AI to predict, identify, design, construct, screen, select and scale production of novel biologic drug candidates, and learn from the data we generate. Our goal is to become the partner o...

IndustryBiotechnology
IPO DateJul 22, 2021
CEOSean McClain
Employees169
Stock ExchangeNASDAQ
Ticker SymbolABSI
Full Company Profile

Financial Performance

In 2020, Absci's revenue was $4.78 million, an increase of 132.04% compared to the previous year's $2.06 million. Losses were -$14.35 million, 118.0% more than in 2019.

Financial Statements

News

Absci Opens Door to New Biotechnology Campus

Vancouver, Washington headquarters expands company's ability to accelerate discovery and development of next generation biologic drugs Vancouver, Washington headquarters expands company's ability to acc...

2 days ago - GlobeNewsWire

Absci to Report Third Quarter Financial Results on November 9, 2021

VANCOUVER, Wash., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic po...

1 week ago - GlobeNewsWire

FMR LLC's Top 5 Buys in September

FMR LLC, the Boston-based asset management company commonly known as Fidelity, disclosed this month that its top-five trades during September included new buys in Toast Inc. ( TOST , Financial), Graphit...

Other symbols:CLDXGRPHTOSTZI
1 week ago - GuruFocus

EQRx, Absci Ink Protein-Based Therapeutics Development Pact

EQRx and Absci Corporation (NASDAQ: ABSI) have announced a discovery collaboration for protein-based therapeutics. Deal terms were not disclosed.

2 weeks ago - Benzinga

EQRx and Absci Announce Partnership to Discover and Develop Next-Generation Protein-Based Drugs

Absci's AI-powered discovery and development platform to further expand EQRx's portfolio of innovative, affordable medicines Absci's AI-powered discovery and development platform to further expand EQRx'...

2 weeks ago - GlobeNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Absci Corporation - ABSI

New York, New York--(Newsfile Corp. - September 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Absci Corporation ("Absci" or the "Company") (NASDAQ: ABSI). Such investors ar...

1 month ago - Newsfile Corp

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Absci Corporation - ABSI

NEW YORK, Sept. 20, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Absci Corporation ("Absci" or the "Company") (NASDAQ: ABSI).

1 month ago - PRNewsWire

Absci to Participate in the BofA Securities 2021 Tech Solutions for Drug Discovery Conference

VANCOUVER, Wash., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning and synthetic biology to expand the therapeutic pote...

1 month ago - GlobeNewsWire

Absci Reports Second Quarter 2021 Financial and Operating Results

VANCOUVER, Wash., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning and synthetic biology to expand the therapeutic pote...

1 month ago - GlobeNewsWire

Absci Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

VANCOUVER, Wash., July 26, 2021 (GLOBE NEWSWIRE) -- Absci Corporation (“Absci”), the synthetic biology company unlocking the potential of proteins as next-generation therapeutics, today announced the cl...

2 months ago - GlobeNewsWire

Shares of protein discovery platform Absci pop in market debut

Absci Corp., a Vancouver company behind a multi-faceted drug development platform, went public on Thursday. It's another sign of snowballing interest in new approaches to drug development – a traditiona...

3 months ago - TechCrunch

Absci Announces Pricing of Initial Public Offering

VANCOUVER, Wash., July 21, 2021 (GLOBE NEWSWIRE) -- Absci Corporation (“Absci”), the synthetic biology company unlocking the potential of proteins as next-generation therapeutics, today announced the pr...

3 months ago - GlobeNewsWire

Vancouver biotech firm Absci files for IPO

It plans to list on the Nasdaq exchange under the ticker symbol ABSI.

3 months ago - The Oregonian

AbSci to become publicly traded

Vancouver biotech company AbSci announced its intention to file for an initial public offering on Wednesday.

3 months ago - The Columbian

Absci IPO Registration Document (S-1)

Absci Corporation has filed to go public with an IPO on the NASDAQ.

3 months ago - SEC